Role of Fibrocytes in Chronic Obstructive Pulmonary Disease

NCT01196832 | Completed

• 2 other identifiers: CHUBX 2010/052010-A00248-31
• Study Type: interventional
• Target: 115
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling. Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation. Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

Conditions

Chronic Obstructive Pulmonary Disease

Outcome Measures

Primary Outcomes (2)

• Number of circulating blood fibrocytes

  Sampling of blood in Chronic obstructive pulmonary disease patients

  Day 1

• Number of circulating blood fibrocytes

  Sampling of blood in Chronic obstructive pulmonary disease patients

  2 months

Secondary Outcomes (6)

• Characterization of fibrocytes

  Day 1 and at 2 months

• Differenciation of blood fibrocytes

  Day 1 and at 2 months

• Chemotactism of blood fibrocytes

  Day 1 and at 2 months

• Number of exacerbation

  12 months after V2

• Mortality

  12 months after V2

Study Arms (2)

Chronic obstructive pulmonary disease patients

EXPERIMENTAL

COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux. Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis.

Procedure: blood sample; Procedure: Clinical and functional evaluation

Control group

OTHER

Subjects without any history of lung disease and with normal lung function testing

Procedure: blood sample

Interventions

blood sample PROCEDURE

blood sample for fibrocytes analysis

Chronic obstructive pulmonary disease patients; Control group

Clinical and functional evaluation PROCEDURE

Plethysmography, Carbon monoxide capacity of transfer , arterial gaz

Chronic obstructive pulmonary disease patients

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
• Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
• Written informed consent

You may not qualify if:

• Subject without any social security or health insurance
• Asthma, lung fibrosis or idiopathic pulmonary hypertension
• Chronic viral infections (hepatitis, HIV)

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Study Sites (1)

CHU de Bordeaux

Pessac, 33604, France

Location

Related Publications (1)

• Dupin I, Allard B, Ozier A, Maurat E, Ousova O, Delbrel E, Trian T, Bui HN, Dromer C, Guisset O, Blanchard E, Hilbert G, Vargas F, Thumerel M, Marthan R, Girodet PO, Berger P. Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway. J Allergy Clin Immunol. 2016 Apr;137(4):1036-1042.e7. doi: 10.1016/j.jaci.2015.08.043. Epub 2015 Oct 23.

  PMID: 26602164 RESULT

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Patrick BERGER, PUPH

  University Hospital Bordeaux (France)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 1, 2010
• First Posted: September 9, 2010
• Study Start: March 11, 2011
• Primary Completion: March 1, 2016
• Study Completion: May 31, 2016
• Last Updated: June 9, 2026

Record last verified: 2022-02

Locations

FR (1)